Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials.
Food and Drug Administration
clinical trial
hepatitis C
Journal
Journal of virus eradication
ISSN: 2055-6640
Titre abrégé: J Virus Erad
Pays: England
ID NLM: 101654142
Informations de publication
Date de publication:
18 Sep 2019
18 Sep 2019
Historique:
entrez:
9
11
2019
pubmed:
9
11
2019
medline:
9
11
2019
Statut:
epublish
Résumé
Under representation of black subjects in trials of hepatitis C virus (HCV) direct-acting antivirals (DAAs) complicates assessment of differential outcomes for black individuals Twenty-six trials were pooled and included 2869 individuals with HCV GT1 alone and 742 individuals with both HCV GT1 and HIV. Of the 2869 HCV GT1-mono-infected subjects, 408 (14.2%) were black. Sustained virological response assessed 12 weeks following cessation of treatment (SVR12) was 92%-100% in black individuals and 87.5%-100.0% in non-black individuals. In pooled analyses, SVR12 was numerically similar between black and non-black subjects (97.1% No notable SVR12 differences were seen in between black and non-black individuals with HCV GT1 alone. Although a numerical difference was observed between black and non-black individuals with both HCV GT1 and HIV, this finding was driven by results from a single trial and may be due to reasons other than ethnicity: 19 subgroup analyses showed baseline characteristics did not affect SVR12 for black and non-black individuals with both HCV GT1 and HIV.
Types de publication
Editorial
Langues
eng
Pagination
138-144Informations de copyright
© 2019 The Authors. Journal of Virus Eradication published by Mediscript Ltd.
Références
N Engl J Med. 2015 Aug 20;373(8):705-13
pubmed: 26196665
Nature. 2009 Sep 17;461(7262):399-401
pubmed: 19684573
Open Forum Infect Dis. 2017 Dec 09;5(1):ofx264
pubmed: 29308413
Ann Intern Med. 2017 May 02;166(9):637-648
pubmed: 28319996
JAMA. 2012 Dec 26;308(24):2584-93
pubmed: 23268517
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492
pubmed: 30215672
Hepatology. 2017 Jun;65(6):2124-2125
pubmed: 28100007
Hepatology. 2017 Nov;66(5):1402-1412
pubmed: 28608973
Ann Intern Med. 2014 Mar 18;160(6):369-79
pubmed: 24723077
Hepatology. 2018 Mar;67(3):847-857
pubmed: 29108121
Hepatology. 2015 Nov;62(5):1353-63
pubmed: 26171595
Clin Infect Dis. 2017 Jun 15;64(12):1721-1723
pubmed: 28199517
Clin Infect Dis. 2017 Jul 01;65(1):6-12
pubmed: 28369210
Antivir Ther. 2017;22(6):481-493
pubmed: 27934775
Hepatology. 2016 Feb;63(2):437-44
pubmed: 26547499
N Engl J Med. 2015 Aug 20;373(8):714-25
pubmed: 26196502
Hepatology. 2016 Aug;64(2):405-14
pubmed: 27115523
Lancet Infect Dis. 2016 Jul;16(7):797-808
pubmed: 26922272
Clin Gastroenterol Hepatol. 2011 Jun;9(6):509-516.e1
pubmed: 21397729
Ann Intern Med. 2013 May 7;158(9):658-66
pubmed: 23440167
Hepatology. 2017 Feb;65(2):426-438
pubmed: 27775854
Open Forum Infect Dis. 2017 Apr 05;4(2):ofx062
pubmed: 28534036
J Natl Med Assoc. 2016 Feb;108(1):24-9
pubmed: 26928485
JAMA. 2015 Mar 24-31;313(12):1223-31
pubmed: 25706092
Clin Infect Dis. 2017 Jun 15;64(12):1711-1720
pubmed: 28199525
Hepatology. 1999 Sep;30(3):787-93
pubmed: 10462387
Clin Infect Dis. 2009 Nov 15;49(10):1605-15
pubmed: 19842982